AI English summary of an SEC filing — figures as filed
Dexcom DXCMDexcom said worldwide revenue for Q1 2025 grew 12% on a reported basis to $1.036 billion, compared to $921.0 million in the prior-year period. U.S. revenue grew 15% and international revenue grew 7% on a reported basis.
Key points
AI summaryDexcom said worldwide revenue for Q1 2025 grew 12% on a reported basis to $1.036 billion, compared to $921.0 million in the prior-year period. U.S. revenue grew 15% and international revenue grew 7% on a reported basis.
The company said GAAP operating income for Q1 was $133.7 million, or 12.9% of revenue, an increase compared to $101.1 million, or 11.0% of revenue, in the prior-year period. Non-GAAP operating income was $143.1 million, or 13.8% of reported revenue, compared to $140.2 million, or 15.2% of reported revenue, in the prior-year period.
Dexcom updated its fiscal 2025 guidance for Non-GAAP Gross Profit Margin to approximately 62%, citing incremental costs related to near-term supply dynamics as the company reestablishes optimal finished goods inventory levels as the reason for the reduction relative to prior guidance. It reiterated its revenue guidance of $4.60 billion, representing 14% growth.
The company said its Board of Directors authorized a share repurchase program of up to $750.0 million of Dexcom's outstanding common stock, with a repurchase period ending no later than June 30, 2026. The timing and method of repurchases are at the company's discretion, and the program does not obligate Dexcom to repurchase any dollar amount or number of shares.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
Q1 Revenue $1.036 billion, Up 12% on Reported Basis
Dexcom said worldwide revenue for Q1 2025 grew 12% on a reported basis to $1.036 billion, compared to $921.0 million in the prior-year period. U.S. revenue grew 15% and international revenue grew 7% on a reported basis.
Source · Based on the filing body and exhibits
GAAP and Non-GAAP Operating Income and Operating Margin
The company said GAAP operating income for Q1 was $133.7 million, or 12.9% of revenue, an increase compared to $101.1 million, or 11.0% of revenue, in the prior-year period. Non-GAAP operating income was $143.1 million, or 13.8% of reported revenue, compared to $140.2 million, or 15.2% of reported revenue, in the prior-year period.
Source · Based on the filing body and exhibits
Non-GAAP Gross Profit Margin Guidance Adjusted
Dexcom updated its fiscal 2025 guidance for Non-GAAP Gross Profit Margin to approximately 62%, citing incremental costs related to near-term supply dynamics as the company reestablishes optimal finished goods inventory levels as the reason for the reduction relative to prior guidance. It reiterated its revenue guidance of $4.60 billion, representing 14% growth.
Source · Based on the filing body and exhibits
$750 million Share Repurchase Program Authorized
The company said its Board of Directors authorized a share repurchase program of up to $750.0 million of Dexcom's outstanding common stock, with a repurchase period ending no later than June 30, 2026. The timing and method of repurchases are at the company's discretion, and the program does not obligate Dexcom to repurchase any dollar amount or number of shares.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…